Norman Wolmark
Overview
Explore the profile of Norman Wolmark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
25554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geyer Jr C, Untch M, Huang C, Mano M, Mamounas E, Wolmark N, et al.
N Engl J Med
. 2025 Jan;
392(3):249-257.
PMID: 39813643
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The...
2.
ODwyer P, Wolmark N, Hawkins D, Schnall M, Dancey J, Blanke C, et al.
J Clin Oncol
. 2024 Sep;
42(33):3905-3910.
PMID: 39288338
No abstract available.
3.
Ganz P, Cecchini R, White J, Vicini F, Arthur D, Rabinovitch R, et al.
J Natl Cancer Inst
. 2024 Sep;
117(1):103-111.
PMID: 39254630
Background: NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of...
4.
Chibaudel B, Raeisi M, Cohen R, Yothers G, Goldberg R, Bachet J, et al.
J Clin Oncol
. 2024 Sep;
42(35):4187-4195.
PMID: 39231393
Purpose: The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC....
5.
Foldi J, Carleton N, Anderson S, Rastogi P, Lee A, Balic M, et al.
J Natl Cancer Inst
. 2024 Aug;
117(1):163-168.
PMID: 39128018
We evaluated differences in long-term outcomes of invasive lobular carcinoma vs breast cancers of no special type treated with anthracycline-based adjuvant chemotherapy using 4 National Surgical Adjuvant Breast and Bowel...
6.
Rastogi P, Bandos H, Lucas P, J van t Veer L, Wei J, Geyer Jr C, et al.
J Clin Oncol
. 2024 Jul;
42(30):3561-3569.
PMID: 39047219
Purpose: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients...
7.
Sparano J, Crager M, Gray R, Tang G, Hoag J, Baehner F, et al.
NEJM Evid
. 2024 Jul;
3(8):EVIDoa2300267.
PMID: 39041867
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative...
8.
Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C, et al.
Breast Cancer Res
. 2024 May;
26(1):83.
PMID: 38790033
No abstract available.
9.
Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C, et al.
Breast Cancer Res
. 2024 Apr;
26(1):69.
PMID: 38650031
Background: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA...
10.
Mamounas E, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas P, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1984-1991.
PMID: 38376912
Purpose: BCI (H/I) has been shown to predict extended endocrine therapy (EET) benefit. We examined BCI (H/I) for EET benefit prediction in NSABP B-42, which evaluated extended letrozole therapy (ELT)...